Stablepharma is delighted to announce another new recruit to the Science Team in Spain

Stablepharma announce another new recruit to the Science team in Madrid, Spain based at Stablepharma’s R&D Center of Excellence (CoE) in Qube Technology Park

Medannex’s monoclonal antibody MDX-124 highly active in pancreatic cancer models

Data shows powerful synergy in combination with standard cancer treatments

CEO Update | 24 January 2022

I am looking forward to our first in-person events of 2022 this week, headlined by the BIA’s Annual Gala Dinner. This is a chance to celebrate the fantastic work undertaken by the sector throughout 2021 and raise money for our Charity Partner of the Year, Kidney Research UK. There are a few individual tickets left, so do book quickly if you are interested in attending.

Virology Research Services Chooses Discovery Park as it relocates London team

A team of virologists move to Discovery Park to expand operations. Demand for lab and manufacturing space continues at Discovery Park to support the UK’s booming life science industry.

BioIVT Launches GMP Grade Human AB Serum to Facilitate the Development and Manufacturing of Cell and Gene Therapies

This cell culture supplement can be used to manufacture both autologous and allogeneic cell therapies.

BIA response to conclusion of NICE methods and processes review

The National Institute for Health and Care Excellence (NICE) has published its conclusions to its review of its methods and processes for Health Technology Assessments. 

What next for the COVID-19 taskforces?

Dr Ruth McKernan CBE, former chair of the BioIndustry Association and former Chair of Innovate UK, discusses the future of antivirals in relation to COVID-19 and how this works with current government processes.

Arecor commences US phase I clinical trial of AT247 ultra-rapid insulin in combination with an insulin pump

First patient dosed in potential game-changing diabetes combination therapy

The Oxford Science Park appoints Jitesh Patel as Development Manager

New role enables accelerated delivery of buildings for existing & new occupiers

Pneumagen Raises £3.8 million to Advance the Phase II Clinical Development of Neumifil, a Pan-antiviral, Intranasal Drug for the Prophylaxis and Treatment of Viral Respiratory Tract Infections (RTIs)

Pneumagen is a clinical stage biotech company developing Neumifil, a pan-antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs).